NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
1、“Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder
2、Exclusive“Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NADH powder
3、Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMN powder
4、Provide one-stop product solution customization service
The main methods of NADH powder preparation include extraction, fermentation, fortification, biosynthesis and organic matter synthesis. Compared with other preparations, the whole enzyme become the mainstream method owing to the advantages of pollution free, high level of purity and stability.
Improved energy levels
Not only does NADH act as an important coenzyme in aerobic respiration, the [H] of NADH also carries a large amount of energy. Studies have demonstrated that extracellular use of NADH promotes increased intracellular ATP levels, suggesting that NADH penetrates cell membranes and elevates intracellular energy levels. On a macro level, exogenous supplementation of NADH helps to restore energy and enhance appetite. The increase in energy levels in the brain also helps to improve mental performance and sleep quality. NADH has been used overseas to improve chronic fatigue syndrome, increase exercise endurance, jet lag and other areas.
Cellular protection
NADH is a strong antioxidant that naturally occurs in cells and reacts with free radicals to inhibit lipid peroxidation, protecting mitochondrial membranes and mitochondrial function. It has been found that NADH can reduce oxidative stress in cells caused by various factors such as radiation, drugs, toxic substances, strenuous exercise and ischemia, thus protecting vascular endothelial cells, hepatocytes, cardiomyocytes, fibroblasts and neurons. Therefore, injectable or oral NADH is used clinically to improve cardiovascular and cerebrovascular diseases, and as an adjunct to cancer radiotherapy. Topical NADH has been shown to be effective in the treatment of rosacea and contact dermatitis.
Promotion of neurotransmitter production
Studies have shown that NADH significantly promotes the production of the neurotransmitter dopamine, a chemical signal that is essential for short-term memory, involuntary movements, muscle tone and spontaneous physical responses. It also mediates the release of growth hormone and determines muscle movement. Without sufficient dopamine, muscles become stiff. Parkinson's disease, for example, is caused in part by a disruption of dopamine synthesis in brain cells. Preliminary clinical data suggest that NADH can help improve the symptoms of Parkinson's disease [9]. NADH also promotes the biosynthesis of norepinephrine and serotonin, showing good potential for use in the relief of depression and Alzheimer's disease.
NADH is synthesized by the body and thus is not an essential nutrient. It does require the essential nutrient nicotinamide for its synthesis, and its role in energy production is certainly an essential one. In addition to its role in the mitochondrial electron transport chain, NADH is produced in the cytosol. The mitochondrial membrane is impermeable to NADH, and this permeability barrier effectively separates the cytoplasmic from the mitochondrial NADH pools. However, cytoplasmic NADH can be used for biologic energy production. This occurs when the malate-aspartate shuttle introduces reducing equivalents from NADH in the cytosol to the electron transport chain of the mitochondria. This shuttle mainly occurs in the liver and heart.
The action of supplemental NADH is unclear. Oral NADH supplementation has been used to combat simple fatigue as well as such mysterious and energy-sapping disorders as chronic fatigue syndrome and fibromyalgia. Researchers are also studying the value of NADH supplements for improving mental function in people with Alzheimer's disease, and minimizing physical disability and relieving depression in people with Parkinson's disease. Some healthy individuals also take NADH supplements orally to improve concentration and memory capacity, as well as to increase athletic endurance. However, to date there have been no published studies to indicate that using NADH is in any way effective or safe for these purposes
First, inspect the factory. After some screening, NADH companies that directly face consumers pay more attention to brand building. Therefore, for a good brand, quality is the most important thing, and the first thing to control the quality of raw materials is to inspect the factory. Bontac company actually manufacturing NADH powder of high quality with the caterias of SGS. Secondly, the purity is tested. Purity is one of the most important parameters of NMN powder. If high purity NMN cannot be guaranteed, the remaining substances are likely to exceed the relevant standards. As the attached certificates demonstrates that the NADH powder produced by Bontac reach the purity of 99%. Finally, a professional test spectrum is needed to prove it. Common methods for determining the structure of an organic compound include Nuclear Magnetic Resonance Spectroscopy (NMR) and high-resolution mass spectrometry (HRMS). Usually through the analysis of these two spectra, the structure of the compound can be preliminarily determined.
Introduction Ginsenoside Rh2 nanoliposome formulation has been proved to effectively target and deliver drugs to the tumor site, with less side effects and higher treatment efficiency, holding great promise in the treatment of tumors including breast cancer. Dilemma of traditional tumor therapies The traditional tumor therapies (eg. surgery, radiation, and chemotherapy) carry the high risks of damaging normal tissues and incompletely eradicating the cancer. Strikingly, nanotechnology opens up novel opportunities for tumor treatment, which can enhance earlier diagnosis through in vitro assays, promote imaging capabilities for diagnosis and treatment monitoring, and improve therapeutic outcomes by refining targeting precision, augmenting localized drug efficacy as well as minimizing systemic toxicity. Limitations of conventional liposome formulations The conventional liposome formations encounter a lot of bottlenecks in improving the progress of tumor microenvironment, a vital complex ecosystem for cancer development and metastasis. In addition, these formulations face the trouble (eg. issues related to religion tradition and vegetarianism) brought by cholesterol, an ingredient of traditional liposomes. Moreover, there are disadvantages of complicated fabrication process, low targeting efficiency of ligand-modified liposomes as well as extended circulation time of liposomes caused by the utilization of polyethylene glycol. Merits of PTX-Rh2-Lipo PTX-Rh2-lipo, a potential nanomedicine, has an overtly smaller particle size and higher zeta potential when compared with PTX-C-Lipo. Both types of liposomes show analogous encapsulation and stabilization abilities, as manifested by similar polydispersity index, encapsulation efficiency, and loading efficiency. Different from conventional wooden liposomes, PTX-Rh2-Lipo has the merits of enhanced uptake in tumor-associated fibroblasts L929 and 4T1 breast cancer cells, high targeting and penetration capacity, cytotoxicity against L929 fibroblasts, normalization of the vessel network, and depletion of stromal collagen. Conclusion Rh2-lipo cannot kill 4T1 breast cancer cells alone, despite of its stronger penetration ability in the tumors. Yet, it can act as a delivery vehicle for paclitaxel (PTX) to enhance its antitumor properties. Specifically, in this novel Rh2-Lipo-based nano-carrier PTX-Rh2-lipo, ginsenoside Rh2 can not only serve as a multifunctional membrane material to stabilize the structure and prolong the blood circulation of liposomes, but also works as an active ingredient to synergically enhance the efficacy of anti-cancer drugs by remodeling tumor-associated microenvironment and stimulating the immune system. Reference [1] Alrushaid N, Khan FA, Al-Suhaimi EA, et al. Nanotechnology in Cancer Diagnosis and Treatment. Pharmaceutics. 2023; 15(3):1025. doi: 10.3390/pharmaceutics15031025 [2] Hong C, Liang J, Xia J, et al. One Stone Four Birds: A Novel Liposomal Delivery System Multi-functionalized with Ginsenoside Rh2 for Tumor Targeting Therapy. Nanomicro Lett. 2020;12(1):129. doi:10.1007/s40820-020-00472-8 [3] Hong C, Wang A, Xia J, et al. Ginsenoside Rh2-Based Multifunctional Liposomes for Advanced Breast Cancer Therapy. Int J Nanomedicine. 2024;19:2879-2888. doi:10.2147/IJN.S437733 BONTAC Ginsenosides BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team. BONTAC has rich R&D experience and advanced technology in the biosynthesis of rare ginsenosides Rh2/Rg3, with pure raw materials, higher conversion rate and higher content (up to 99%). One-stop service for customized product solution is available in BONTAC. With unique Bonzyme enzymatic synthesis technology, both S-type and R-type isomers can be accurately synthesized here, with stronger activity and precise targeting action. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.
Introduction On Feb 25-29, 2024, BONTAC was invited to 2024 Boao Healthy Food Science Conference & Exposition (FHE 2024) and made a discussion with the industry elites on the innovation of science and technology as well as the trend towards industry development in the health food area. Conference profile There are 15 academicians, 300 report experts, and over 2000 delegates from around the world gathering around the conference. More than 40 professional forums are planned in FHE 2024, attracting the active participation of domestic and foreign industry leaders such as Danone, Nestle and Pepsi. BONTAC star products in FHE 2024 By dirt of its innovative technology and strong R&D strength in the field of green biosynthesis, BONTAC stands out from the crowd. To date, there are over 170 global patents by BONTAC. BONTAC star products, including NMN, NADH and ginsenoside Rh2/Rg3, are present in FHE 2024, which are highly recognized by many brand owners. Many attendees are attracted to learn more and negotiate with BONTAC for further cooperation. Notably, Professor Chen Junshi from Chinese Academy of Engineering visited the booth of BONTAC, gave guidance to the team of BONTAC and highly praised the innovative achievements in the field of biosynthesis. Facilitating the development of high-quality health food via innovation of science and technology From the traditional healthcare with herbs to modern precision nutrition, health has always been the focus of people. With the progress of science and technology, the development of new functional nutrients has gradually relied on the support of technical innovation. In various niche areas of health, NMN has emerged as an essential force in health industry by leverage of its unique science base and broad application prospect. Mounting scientific research and clinical practice have attested the obvious efficacy of NMN in promoting the immunity, improving the cardiovascular health, and alleviating the fatigue. Conclusion FHE 2024 is the first domestic platform for the communication of scientific evidence on health beneficial food. In the future, BONTAC will continue to provide comprehensive solutions for anti-aging series products including coenzyme and natural extracts, and facilitate the development of high-quality food via innovation of science and technology. About BONTAC BONTAC has been dedicated to the green biosynthesis for 12 years, with the intention of creating a better life for human beings. Up till now, there are 173 patents by BONTAC. As the pioneer of NMN industry, BONTAC is the first manufacturer to launch NMN mass production, with the first whole-enzyme catalysis technology around the world. At present, BONTAC has become the leading enterprise in niche areas of coenzyme products. Notably, BONTAC is the NMN raw material supplier of famous David Sinclair team at the Harvard University, who uses the raw materials of BONTAC in a paper titled “Impairment of an Endothelial NAD+-H2S Signaling Network Is a Reversible Cause of Vascular Aging”.
Introduction In the presence of oxygen, tumors produce adenosine triphosphate (ATP) through glycolysis instead of mitochondrial oxidative phosphorylation, a phenomenon known as the “Warburg effect”. Aerobic glycolysis caused by an altered tumor microenvironment is an important factor contributing to malignant tumor progression. Ginsenoside Rh2 (Rh2) can specifically reverse the shift from tumor aerobic glycolysis to oxidative phosphorylation to modulate the metabolic behavior of non-small cell lung cancer (NSCLC), ultimately promoting the “benignization” of NSCLC. The suppressive impacts of Rh2 on the malignant progression of NSCLC Rh2 inhibits the proliferation, invasion and migration, while promoting the apoptosis of NSCLC cells. Meanwhile, Rh2 treatment represses tumor lymph angiogenesis, as manifested by the obviously reduced expression of CD31. Moreover, Rh2 hinders the metastasis of NSCLC by inhibiting the epithelial mesenchymal transition (EMT), as evidenced by the upregulation of E-cadherin and downregulation of N-cadherin in lung tissues post Rh2 treatment. Underlying targets and mechanisms of Rh2 against NSCLC Rh2 hampers NSCLC aerobic glycolytic capacity, including glucose uptake and lactate production, through the HIF1-α/PDK4 pathway. Specifically, Rh2 targets hypoxia-inducible factor HIF-1α to downregulate its expression, subsequently reducing the expression of PDK4, a pivotal enzyme during the glucose oxidation process. By this way, Rh2 further suppresses aerobic glycolysis, promotes mitochondrial aerobic oxidative process, and stimulates the production of reactive oxygen species (ROS), thereby promoting tumor cells to enter the normal apoptotic program. The efficacy of Rh2 combined with DCA in NSCLC Sodium dichloroacetate (DCA), an inhibitor of pyruvate dehydrogenase kinase (PDKs), has been commonly used in clinical practice as an anticancer drug targeting glycolysis, yet it has hepatotoxicity and neurotoxicity at high doses. Notably, the combination of Rh2 with DCA dramatically reverses the biometabolic behaviors of tumors, and further reduces the dosage of DCA, which decreases the toxicity of DCA, greatly increasing the drug efficacy. Conclusion Rh2 shifts tumor metabolism from aerobic glycolysis to oxidative phosphorylation through regulating the HIF1-α/PDK4 axis in NSCLCs. It activates the apoptotic program of NSCLCs and exerts a potentiating and toxicity-reducing effect when used in combination with chemotherapeutic agents DCA, hinting its potential as an adjuvant against tumors. Reference Liu X, Li J, Huang Q, et al. Ginsenoside Rh2 shifts tumor metabolism from aerobic glycolysis to oxidative phosphorylation through regulating the HIF1-α/PDK4 axis in non-small cell lung cancer. Mol Med. 2024;30(1):56. Published 2024 Apr 26. doi:10.1186/s10020-024-00813-y BONTAC Ginsenosides BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team. BONTAC has rich R&D experience and advanced technology in the biosynthesis of rare ginsenosides Rh2/Rg3, with pure raw materials, higher conversion rate and higher content (up to 99%). One-stop service for customized product solution is available in BONTAC. With unique Bonzyme enzymatic synthesis technology, both S-type and R-type isomers can be accurately synthesized here, with stronger activity and precise targeting action. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be responsible for any claims, damages, losses, expenses, or costs arising directly or indirectly from your reliance on the information and material on this website.